Ascendis Pharma (ASND) cash on hand
Ascendis Pharma (ASND) held cash of €616.04M at the end of fiscal 2025 (December 31, 2025). That is 10.1% higher than the €559.54M of fiscal 2024. Figures as of 18 Nov 2026, 01:12 UTC, from Yahoo Finance.
Key facts
- Cash, fiscal 2025
- €616.04M
- Change on fiscal 2024
- +10.1%
- Highest on record
- €735.46Mfiscal 2022
- Lowest on record
- €399.44Mfiscal 2023
- Fiscal years on record
- 42022–2025
Figures as of . Statements from Yahoo Finance. Amounts are in EUR. Figures, not advice.
Ascendis Pharma cash on hand, in more detail
Across the 4 fiscal years on record (2022–2025), the highest was €735.46M in fiscal 2022 and the lowest €399.44M in fiscal 2023.
Cash by fiscal year
Ascendis Pharma cash on hand, year by year
| Fiscal year | Cash | Change | Year ended |
|---|---|---|---|
| 2025 | €616.04M | 10.1% up | |
| 2024 | €559.54M | 40.1% up | |
| 2023 | €399.44M | 45.7% down | |
| 2022 | €735.46M | — |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Cash is the cash, cash equivalents and short-term investments on the balance sheet at the fiscal year-end, shown for the fiscal years the market data feed covers because the older SEC record counts cash and equivalents alone.
How to read it
Cash is the cushion that pays for bad years, buybacks and acquisitions; compare it with total debt to see whether the company is a net borrower.
Cash at health care companies of similar size
| Company | Cash | Fiscal year |
|---|---|---|
| Revvity RVTY | $919.86M | 2025 |
| Exelixis EXEL | $1.06B | 2025 |
| Neurocrine Biosciences NBIX | $1.48B | 2025 |
| Ascendis Pharma ASND | €616.04M | 2025 |
The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.
Ascendis Pharma, figure by figure
- Ascendis Pharma market cap
- Ascendis Pharma revenue
- Ascendis Pharma earnings
- Ascendis Pharma earnings per share (EPS)
- Ascendis Pharma P/E ratio
- Ascendis Pharma P/S ratio
- Ascendis Pharma P/B ratio
- Ascendis Pharma free cash flow
- Ascendis Pharma operating margin
- Ascendis Pharma dividend
- Ascendis Pharma shares outstanding
- Ascendis Pharma total debt
- Ascendis Pharma total assets
- Ascendis Pharma return on equity (ROE)
- Ascendis Pharma return on invested capital (ROIC)
Ascendis Pharma (ASND) overview: price, valuation and scorecardAll health care companies by market value
Ascendis Pharma cash on hand: questions and answers
How much cash does Ascendis Pharma have?
Ascendis Pharma (ASND) held cash of €616.04M at the end of fiscal 2025 (December 31, 2025). That is 10.1% higher than the €559.54M of fiscal 2024.
What are the highest and lowest cash figures on record for Ascendis Pharma?
Across the 4 fiscal years on record (2022–2025), the highest was €735.46M in fiscal 2022 and the lowest €399.44M in fiscal 2023.
How is Ascendis Pharma's cash calculated?
Cash is the cash, cash equivalents and short-term investments on the balance sheet at the fiscal year-end, shown for the fiscal years the market data feed covers because the older SEC record counts cash and equivalents alone.
Fiscal years are named for the calendar year they end in.
Learn: cash on hand
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “Ascendis Pharma (ASND) cash on hand”, data as of 18 November 2026. https://funkfolio.com/stock/ASND/cash
Underlying data: Yahoo Finance.